CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Net product sales	$ 957,367	$ 857,468	$ 2,739,745	$ 2,475,869
Sanofi collaboration revenue	245,175	144,392	677,670	527,500
Bayer Collaboration Revenue	236,625	191,298	640,919	562,786
Other revenue	61,506	26,964	231,446	67,445
Total revenues	1,500,673	1,220,122	4,289,780	3,633,600
Expenses:
Research and development	529,749	543,047	1,547,159	1,573,089
Selling, general, and administrative	306,766	270,045	910,520	851,760
Cost of goods sold	46,388	29,901	149,774	150,090
Cost of collaboration and contract manufacturing	57,844	14,327	141,547	74,923
Total expenses	940,747	857,320	2,749,000	2,649,862
Income from operations	559,926	362,802	1,540,780	983,738
Other income (expense):
Other income, net	11,861	3,575	2,048	8,937
Interest expense, net	(6,182)	(496)	(19,084)	(4,387)
Total other income (expense)	5,679	3,079	(17,036)	4,550
Income before income taxes	565,605	365,881	1,523,744	988,288
Income tax expense	(177,288)	(101,077)	(498,752)	(345,881)
Net income	$ 388,317	$ 264,804	$ 1,024,992	$ 642,407
Net income per share - basic	$ 3.64	$ 2.53	$ 9.66	$ 6.14
Net income per share - diluted	$ 3.32	$ 2.27	$ 8.84	$ 5.51
Weighted average shares outstanding - basic	106,706	104,833	106,108	104,586
Weighted average shares outstanding - diluted	117,028	116,466	115,994	116,567
Statements of Comprehensive Income
Net income	$ 388,317	$ 264,804	$ 1,024,992	$ 642,407
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on marketable securities	21,485	(8,103)	36,645	(11,471)
Unrealized gain on cash flow hedges	2	0	30	0
Comprehensive income	$ 409,804	$ 256,701	$ 1,061,667	$ 630,936